CDXS News & Events

The company said, "Codexis expects that its existing cash, cash equivalents, and short-term investments will be sufficient to fund its planned operations through the end of 2027."

Reports Q1 revenue $15.25M, consensus $14.53M. "Next week Codexis will present new data at the TIDES USA annual meeting demonstrating how the ECO Synthesis Manufacturing Platform enables control over phosphorothioate stereochemistry. Defined stereochemistry confers overall improved product quality and has the potential to deliver increased potency, a step beyond conventional manufacturing technologies," said Alison Moore, President and Chief Executive Officer of Codexis. "We finished the first quarter in a strong financial position with $65.1 million in cash, which we believe remains on track to fund anticipated operations through the end of 2027."

Reports Q4 revenue $38.92M, consensus $35.83M. "Throughout 2025, we made significant strides in demonstrating the importance of our ECO Synthesis Manufacturing Platform to customers in the RNAi industry. We've secured multiple contracts with leading pharma, high growth biotech, and top tier CDMOs, underscoring the commercial potential of our platform," said Alison Moore, president and CEO at Codexis. "We achieved many technological advancements this year, including producing a 10 g siRNA batch utilizing our fully enzymatic synthesis process, as well as a 3 kg siRNA batch from one of our customers utilizing our ligase product. As we look to the year ahead, we are focused on demonstrating the value of our technology to our customers through expanded partnerships, and continuing our history of innovation in oligonucleotide manufacturing."

The company said, "We expect our existing cash, cash equivalents and short-term investments will be sufficient to fund our planned operations through the end of 2027."